CRISPR-Based Therapeutics Blaze an In Vivo Path to the Clinic



Intellia Therapeutics and Regeneron are developing NTLA-2001, a therapeutic that is designed to target liver cells and disable a gene that is responsible for the production of misfolded transthyretin (TTR) protein…more [Intellia Therapeutics]
https://www.genengnews.com/insights/crispr-based-therapeutics-blaze-an-in-vivo-path-to-the-clinic/

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.